Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • COVID-19
    • COVID-19 Update
    • Evaluate Vantage COVID-19 Report
    • COVID-19 Stories from Evaluate Vantage
    • Evaluate’s Business Continuity Plan
  • What We Do
    • Commercial Intelligence
    • Products
      • EvaluatePharma
      • Evaluate Omnium
      • Japan Drug Forecasts
      • European Drug Forecasts
      • Epi Analyzer
    • Evaluate Custom Solutions
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Data Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
  • How We Can Help You
    • Pharma and Biotech
    • Medtech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
    • Careers
      • Current Vacancies
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Data Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Fines & Regulatory Issues

Thumbnail
January 20, 2021

Glaxo joins the Covid-19 delay queue

Thumbnail
January 15, 2021

The biotech resurrection continues

Positive surprises with Lexicon’s Zynquista and DBV’s Viaskin Peanut show that you can never entirely write biotech off.

Article image
Vantage logo
October 07, 2020

Thinking the unthinkable on Covid vaccine approvals

With the EU regulator already reviewing two coronavirus vaccines, could it beat the US FDA to the punch?

Article image
Vantage logo
August 04, 2020

DBV confirms the inevitable

Article image
Vantage logo
May 18, 2020

Covid-19 excitement masks Sorrento’s disastrous capital structure

Article image
Vantage logo
March 17, 2020

Crisis, what crisis? Curevac denies everything

As a Covid-19 vaccine exclusivity and senior management storm engulfs Curevac, the German mRNA specialist insists it’s just conjecture and coincidence.

Article image
Vantage logo
January 22, 2020

Internal FDA documents reveal a familiar story for Sarepta

The unexpected approval of Vyondys 53 followed an FDA power struggle, and turned on a vague commitment from Sarepta, it has emerged.

Article image
Vantage logo
August 22, 2019

Astra could use a voucher to cement roxadustat’s head start

Spending $95m to speed up the anaemia project’s path to approval could be worth the investment for Astrazeneca.

Article image
Vantage logo
August 02, 2019

A recap on the past few months of data digging and analysis

Using EvaluatePharma data Vantage explored investment trends in biopharma and medtech, sales per employee at big drug makers, and the declining number of late-stage…

Article image
Vantage logo
July 11, 2019

Indivior fights off generic challenges but the threat of litigation remains

Weaker than expected generic erosion of its key Suboxone film product has allowed Indivior to raise full-year guidance.

Article image
Vantage logo
May 29, 2019

A silver lining on Mallinckrodt’s Acthar cloud

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

December 10, 2020

Evaluate Vantage 2021 Preview

July 29, 2020

Evaluate Vantage Pharma, Biotech & Medtech Half-Year Review 2020

View more...

Editor's Picks

Vantage logo
January 18, 2021

Aducanumab tops 2021’s biggest potential launches

Vantage logo
January 19, 2021

The pandemic releases its grip on clinical trials

Vantage logo
January 21, 2021

2020 drug approvals rise despite Covid-19

Vantage logo
January 20, 2021

Glaxo joins the Covid-19 delay queue

Vantage logo
January 21, 2021

Merck KGaA’s dual immuno-oncology weapon misfires

Open modal

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)80-1164-4754

Footer menu

  • Terms and Conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2021 Evaluate Ltd.